CAR T, Targeted Therapies, Others as Treatment Options on the Horizon in NETs
The NETRF lends funding to help discover new and emerging treatment options in neuroendocrine tumors, according to Anna Greene, PhD.
Tislelizumab Significantly Boosts Survival in Lung Cancer Trials
A systematic review shows that well-designed randomized clinical trials are necessary to optimize treatment strategies with tislelizumab in lung cancer.
88 Eflapegrastim, a Long-Acting Granulocyte Colony–Stimulating Factor, Administered the Same Day as Chemotherapy in Patients With Early-Stage Breast Cancer: Results From a Multicenter, Open-Label Study
TTFields Therapy Earns EU Approval in Metastatic Non–Small Cell Lung Cancer
Data from the phase 3 LUNAR trial support the Conformité Européenne Mark for tumor treating fields in metastatic non–small cell lung cancer.
New Legislation May Help Reduce Extravasation Rates in Cancer Radiology
Modifying injection methods when administering radioactive therapies may significantly reduce extravasation rates.
Ivonescimab/Chemo Prolongs PFS in 1L Advanced Squamous NSCLC
The phase 3 HARMONi-6 trial found invonescimab plus chemotherapy improved PFS vs tislelizumab plus chemotherapy in squamous NSCLC.
FDA Grants EvoLiver Biopsy Test Breakthrough Device Designation for HCC
MEV01 trial results show that the test achieved an 86% early-stage sensitivity and 88% specificity in surveillance of HCC among patients with cirrhosis.
The Greatest Need in NET Research is Funding
Anna Greene, PhD, spoke about how this under-studied disease needs increased funding and more awareness.
Radiologist Shares Procedures for Radioactive Injections, Extravasation
Extravasation with beta emitters may elicit more drastic adverse effects due to their higher radiation dose.
Funding is the Greatest Need in Neuroendocrine Tumor Research
Anna Greene, PhD, highlights the NETRF’s role as the largest funder of NET research, their current research funding opportunities, and its commitment to patient support.
TPS 89 A Randomized Phase 3 Study of First-Line Saruparib (AZD5305) Plus Camizestrant Versus CDK4/6i Plus Physician’s Choice Endocrine Therapy or CDK4/6i Plus Camizestrant in Patients With HR+/HER2– Advanced Breast Cancer With BRCA1/BRCA2/PALB2 Mutations (EvoPAR-B)
Nadofaragene Firadenovec Yields Responses in BCG-Unresponsive NMIBC
Data from a Japanese trial add to the body of evidence supporting the favorable efficacy and safety of nadofaragene firadenovec for this NMIBC population.
Addressing Unmet Needs in Patients Undergoing Treatment for Rare Lymphomas
Increasing the use of patient-reported outcomes may ensure that practitioners can fully ascertain the impact of treatment for rare lymphomas.
ctDNA May Help to Predict Early Recurrence in Stage III Melanoma
ctDNA levels may help to predict early recurrence for patients with stage III melanoma before adjuvant therapy and during follow-up.
Cancer Mortality Shows Long-Term Declines Despite COVID-19 Pandemic
An annual report on the status of cancer showed that, from 2018 to 2022, the cancer death rate fell for every race and ethnicity.
Fruquintinib Combo Exhibits Manageable Safety Profile in Pretreated mCRC
Treatment-related adverse events of special interest occurred in 64.9% of patients who received fruquintinib and 23.0% of those who received placebo.
Medical Education May Improve Care for Breast Cancer Minority Populations
Photographic and written documentation can help providers recognize inflammatory breast cancer symptoms across diverse populations.
Low Breast Cancer Guideline-Concordant Care Use Indicates Racial Disparities
The use of guideline-concordant care in breast cancer appears to be more common in White populations than Black populations.
90 Contralateral Risk Reduction Mastectomy in Patients With Unilateral Breast Cancer: A Multinational and Multidisciplinary Survey—Physicians’ Perspective
Extent of Prior Therapy Does Not Impact Radiotherapy Response in Myeloma
Disease control following radiotherapy appeared to be optimal in a retrospective cohort of patients with multiple myeloma.
T-DXd With Pertuzumab Improves PFS in HER2+ Metastatic Breast Cancer
Data from the T-DXd monotherapy arm of the phase 3 DESTINY-Breast09 trial will remain blinded until the final PFS analysis.
Zanubrutinib Shows Enhanced Efficacy vs Approved BTKis in R/R CLL
A network meta-analysis of 3 clinical trials sought to compare zanubrutinib vs approved BTKis in relapsed/refractory chronic lymphocytic leukemia.
Sacituzumab Govitecan/Pembrolizumab Yields Significant PFS Improvement in TNBC
Sacituzumab govitecan plus pembrolizumab showed a trend for improved overall survival vs standard of care in patients with untreated PD-L1–positive TNBC.
Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care
Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.
Cemiplimab Continues to Show Benefit Vs Chemo in PD-L1 ≥50% NSCLC
A 5-year follow-up of the phase 3 EMPOWER-Lung 1 showed the greatest survival benefits in patients with NSCLC who have a PD-L1 expression of 90% or more.
Multicancer Early Detection Test Showed Clinical Benefit, Minimal Distress
Patients with a cancer signal detected via multicancer early detection test demonstrated similar results to those who did not in the PATHFINDER cohort study.
High-Dose Radiotherapy Boosts Survival Without Toxicity Increase in LS-SCLC
Phase 3 data support using twice-daily high-dose thoracic radiotherapy plus concurrent chemotherapy as an alternative therapy for patients with LS-SCLC.
Addressing Limitations to Clinical Trial Development for Lymphoma Treatment
Retrospective and real-world registry studies may be necessary to guide clinical decision-making for rarer lymphomas with insufficient prospective data.
Bill Seeks to Require Reporting of Extravasated Tissue in Radiology
Extravasation results in exposing healthy tissue to radiation, which can be highly dosed depending on the isotope used for treatment.
Mindfulness/Activity Program May Ease Anxiety Over Death from Lung Cancer
End-of-life demands card game and mindfulness-based cancer recovery program use may enhance the quality of life for patients with lung cancer.
![“These results and the lack of systemic toxicity observed with [TTFields] provide patients with a promising new treatment option,” according to Joachim Aerts, MD, an investigator of the phase 3 LUNAR trial (NCT02973789).](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F7d7dfad7849391f4be3ebd2cf39c24f5369cfcd1-1200x1176.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "“These results and the lack of systemic toxicity observed with [TTFields] provide patients with a promising new treatment option,” according to Joachim Aerts, MD, an investigator of the phase 3 LUNAR trial (NCT02973789).")
